Vera Bittner

Prof. Dr. Vera Bittner

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2013 in Circulation
Verified
Journal Article
Open access
PDF file
GFGerald F. Fletcher
Gerald F. Fletcher
PAPhilip A. Ades
Philip A. Ades
PKPaul Kligfield
Paul Kligfield
RARoss Arena
Ross Arena
GBGary J. Balady
Gary J. Balady
MWMark A. Williams
Mark A. Williams
T he 2001 version of the exercise standards statement 1 has served effectively to reflect the basic fundamentals of ECG-monitored exercise testing and training of both healthy subjects and patients with cardiovascular disease (CVD) and other disease states. These exercise standards are intended for use by physicians, nurses, exercise physiologists and specialists, technologists, and other healthcare professionals involved in exercise testing and training of these populations. Because of an abundance of new research in recent years, a revision of these exercise standards is appropriate. The revision deals with basic fundamentals of testing and training, with no attempt to duplicate or replace current clinical practice guidelines issued by the American Heart Association (AHA), the American College of Cardiology Foundation (ACCF), and other professional societies.

24 May 2011 in Circulation
Verified
Journal Article
Closed access
MMMichael Miller
Michael Miller
NSNeil J. Stone
Neil J. Stone
CBChristie Ballantyne
Christie Ballantyne
VBVera Bittner
Vera Bittner
MCMichael H. Criqui
Michael H. Criqui
SPSubramanian Pennathur
Subramanian Pennathur

27 September 2007 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
PBPhilip Barter
Philip Barter
AGAntonio M. Gotto
Antonio M. Gotto
JLJohn C. LaRosa
John C. LaRosa
JMJaman Maroni
Jaman Maroni
MSMichael Szarek
Michael Szarek
JFJean-Charles Fruchart
Jean-Charles Fruchart
High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol.

3 July 2002 in JAMA
Verified
Journal Article
Open access
PDF file
DGDeborah Grady
Deborah Grady
DHDavid Herrington
David Herrington
VBVera Bittner
Vera Bittner
RBRoger Blumenthal
Roger Blumenthal
MDMichael Davidson
Michael Davidson
FGfor the HERS Research Group
for the HERS Research Group
The Heart and Estrogen/progestin Replacement Study (HERS) was a randomized, blinded, placebo-controlled trial of the effect of 0.625 mg of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate daily on coronary heart disease (CHD) event risk among 2763 postmenopausal women with documented CHD.1 Overall, during 4.1 years of follow-up, there were no significant differences between the hormone and placebo groups in the primary outcome of CHD events (nonfatal myocardial infarction [MI] plus CHD-related death) or in any secondary cardiovascular outcomes.2-5 However, post-hoc analyses showed a statistically significant time trend, with more CHD events in the hormone group than in the placebo group during the first year of treatment, and fewer in years 3 to 5.2 HERS investigators speculated that early increased risk might be due to a prothrombotic, proarrhythmic, or proischemic effect of treatment that is gradually outweighed by a beneficial effect on the progression of underlying atherosclerosis mediated by the observed favorable changes in low- and high-density lipoprotein cholesterol.2

31 July 2007 in Circulation
Verified
Journal Article
Closed access
PDF file
MWMark A. Williams
Mark A. Williams
WHWilliam L. Haskell
William L. Haskell
PAPhilip A. Ades
Philip A. Ades
EAEzra A. Amsterdam
Ezra A. Amsterdam
VBVera Bittner
Vera Bittner
KSKerry J. Stewart
Kerry J. Stewart
Prescribed and supervised resistance training (RT) enhances muscular strength and endurance, functional capacity and independence, and quality of life while reducing disability in persons with and without cardiovascular disease. These benefits have made RT an accepted component of programs for health and fitness. The American Heart Association recommendations describing the rationale for participation in and considerations for prescribing RT were published in 2000. This update provides current information regarding the (1) health benefits of RT, (2) impact of RT on the cardiovascular system structure and function, (3) role of RT in modifying cardiovascular disease risk factors, (4) benefits in selected populations, (5) process of medical evaluation for participation in RT, and (6) prescriptive methods. The purpose of this update is to provide clinicians with recommendations to facilitate the use of this valuable modality.

22 May 2007 in Circulation
Verified
Journal Article
Open access
PDF file
GBGary J. Balady
Gary J. Balady
MWMark A. Williams
Mark A. Williams
PAPhilip A. Ades
Philip A. Ades
VBVera Bittner
Vera Bittner
PCPatricia Comoss
Patricia Comoss
DSDouglas Southard
Douglas Southard
The American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation recognize that all cardiac rehabilitation/secondary prevention programs should contain specific core components that aim to optimize cardiovascular risk reduction, foster healthy behaviors and compliance to these behaviors, reduce disability, and promote an active lifestyle for patients with cardiovascular disease. This update to the previous statement presents current information on the evaluation, interventions, and expected outcomes in each of the core components of cardiac rehabilitation/secondary prevention programs, in agreement with the 2006 update of the American Heart Association/American College of Cardiology Secondary Prevention Guidelines, including baseline patient assessment, nutritional counseling, risk factor management (lipids, blood pressure, weight, diabetes mellitus, and smoking), psychosocial interventions, and physical activity counseling and exercise training.